Brought to you by 
Biovitrum buys Swedish Orphan for SEK3.5bn in cash and stock
Nov 2009
Executive Summary
Continuing its efforts to transform into solely a specialty pharma company, Sweden's Biovitrum AB will pay SEK3.6bn ($514mm) in cash and stock to buy Swedish Orphan International, a private pan-European company that in-licenses and markets drugs for rare diseases.
Deal Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Full Acquisition
- Includes Earnout
- Payment Includes Stock
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biovitrum buys Swedish Orphan for SEK3.5bn in cash and stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice